載入...
First clinical trials of a new heteropolymer technology agent in normal healthy volunteers and patients with systemic lupus erythematosus: safety and proof of principle of the antigen-heteropolymer ETI-104
Background: The heteropolymer technology was developed to remove pathogens from the circulation. Objectives: To evaluate the safety and tolerability of a single administration and to establish proof of principle for ETI-104 in normal healthy volunteers (NHV) and patients with systemic lupus erythema...
Na minha lista:
| Main Authors: | , , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2004
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1755118/ https://ncbi.nlm.nih.gov/pubmed/15308520 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ard.2003.016691 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|